刘耀琨,郑博,李建平,霍勇

• 1:北京大学第一医院心内科北京大学第一医院心血管疾病研究所

摘要(Abstract)：

<正>在过去的一年里，尽管全球依然笼罩在新型冠状病毒肺炎疫情的阴影之下，但心血管领域的研究者们并未停止探索的脚步，其中国内外冠心病相关的临床研究均取得了令人瞩目的丰硕成果。本文从冠心病介入治疗相关器械、腔内影像学和功能学技术、治疗策略以及药物治疗等方面向大家介绍和总结（图1）。

关键词(KeyWords)： 冠心病;介入治疗;药物治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘耀琨,郑博,李建平,霍勇

参考文献(References)：

• [1] Song L, Xu B, Chen Y, et al. Thinner strut sirolimus-eluting BRS versus EES in patients with coronary artery disease:FUTURE-II trial[J]. JACC Cardiovasc Interv, 2021, 14(13):1450-1462.
• [2] Romaguera R, Salinas P, Gomez-Lara J, et al. Amphilimusversus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease(SUGAR trial)[J]. Eur Heart J,2021:ehab790.
• [3] Kaul U, Bangalore S, Seth A, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes[J]. N Engl J Med, 2015, 373(18):1709-1719.
• [4] Yu B,Liu B,Jia HB,et al. EROSIONⅢ：a randomized trial of OCT-guided intervention in STEMI patients with early infarct artery patency[J/OL]. TCT 2021. Orange County Convention Center,Orlando,Florida.
• [5] Jia H, Dai J, Hou J, et al. Ef fective anti-thrombotic therapy without stenting:intravascular optical coherence tomography-based management in plaque erosion(the EROSION study)[J]. Eur Heart J, 2017, 38(11):792-800.
• [6] Puymirat E, Cayla G, Simon T, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction[J]. N Engl J Med, 2021, 385(4):297-308.
• [7] Tonino PA, De Bruyne B, Pijls NH, et al. Fractional fl ow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med, 2009, 360(3):213-224.
• [8] Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery[J]. N Engl J Med, 2022,386(2):128-137.
• [9] Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve[J]. N Engl J Med, 2018, 379(3):250-259.
• [10] Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J]. N Engl J Med, 2009, 360(10):961-972.
• [11] G?tberg M,Christiansen EH,Gudmundsdottir,et al. iFRSWEDEHEART:Five-Year outcomes of a randomized trial of iFR-Guided vs. FFR-Guided PCI[J/OL]. TCT 2021. Orange County Convention Center,Orlando,Florida.
• [12] Xu B, Tu S, Song L, et al. Angiographic quantitative fl ow ratio-guided coronary intervention(FAVORⅢChina):a multicentre, randomised, sham-controlled trial[J]. Lancet,2021, 398(10317):2149-2159.
• [13] Desch S, Freund A, Akin I, et al. Angiography after out-ofhospital cardiac arrest without ST-segment elevation[J]. N Engl J Med, 2021, 385(27):2544-2553.
• [14] Lemkes JS, Janssens GN, van der Hoeven NW, et al.Coronary angiography after cardiac arrest without ST-segment elevation[J]. N Engl J Med,2019,380(15):1397-1407.
• [15] Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk[J]. N Engl J Med,2021,385(18):1643-1655.
• [16] Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention(TALOSAMI):an investigator-initiated, open-label, multicentre,non-inferiority, randomised trial[J]. Lancet,2021,398(10308):1305-1316.
• [17] Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome:the TICO randomized clinical trial[J]. JAMA,2020,323(23):2407-2416.
• [18] Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes:TWILIGHT-ACS[J]. Eur Heart J,2020,41(37):3533-3545.
• [19] Sibbing D, Aradi D, Jacobshagen C, et al. Guided d e-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention(TROPICAL-ACS):a randomised, open-label, multicentre trial[J]. Lancet,2017,390(10104):1747-1757.
• [20] Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI[J]. N Engl J Med,2019,381(17):1621-1631.
• [21] Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention(HOST-EXAM):an investigator-initiated, prospective,randomised, open-label, multicentre trial[J]. Lancet,2021,397(10293):2487-2496.
• [22] Broch K, Anstensrud AK, Woxholt S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol,2021,77(15):1845-1855.